ClinicalTrials.gg
CompletedNCT03591068Updated Aug 3, 2020Results posted

Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video

A Phase 3 interventional study of Fluticasone Propionate in Nasal Polyposis, sponsored by Optinose US Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-03.

Sponsored by Optinose US Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.

Enrollment
63rd of 71
11 · median 60
Started
2018
with 6 others
Phase 3
25 of 83
4 open now
Registered
44th of 83
by date
Lead sponsor
4 of 83
Optinose US Inc.

Among the 83 studies in Nasal Polyps with a site in United States, this one is the 63rd largest by enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2018, is one of 25 in phase 3, and was the 44th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Nasal Polyps with a site in United States, or all of them as a file.
02

Study summary

This is a 24-week, open-label, multi-center study designed to assess the efficacy and safety of OPN-375 186 μg twice a day in subjects with nasal polyps using Nasoendoscopic video. The total planned number of subjects is approximately 10, with each subject receiving OPN-375 186 μg twice a day.

Read the detailed description

The primary objective of this study is to evaluate the efficacy and safety of OPN-375 186 μg twice a day in adults with Bilateral Nasal Polyps using Nasoendoscopic video. The secondary objectives of this study are to evaluate the safety of OPN-375 via adverse event reports, vital signs, and nasal examination. In addition, to measure any change in subject symptoms and functioning from Baseline to 12 and 24 weeks during the study, using the Sinonasal Outcome Test -22 (SNOT-22), Patient's Global Impression of Change (PGIC), and measurement of nasal polyps by independent, blinded reader, and any changes throughout the study.

03

Conditions studied

  • Nasal Polyposis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women aged 18 years and older at Visit 1 (Baseline/Day1)
  2. Women of child bearing potential must be abstinent, or if sexually active,

    1. be practicing an effective method of (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
    2. be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or
    3. be (amenorrhea for at least 1 year).
  3. Women of must have a negative urine pregnancy test at Visit 1 (Day 1/Baseline)
  4. Must have bilateral nasal polyposis with a grade of 2 or 3 in at least one side of the nasal cavity as determined by a nasal polyp grading scale score measured by nasoendoscopy at Visit 1 (Day 1/Baseline)
  5. Must have a SNOT-22 score of ≥20 at Visit 1(Baseline/Day 1)
  6. Must have been on an adequate dose of an intranasal (e.g. fluticasone propionate, fluticasone furoate, mometasone, triamcinolone, ciclosenide, budesonide, budesonide respules, beclomethasone) for at least 1 month, in the previous 3 months prior to Visit 1 (Day 1/Baseline)
  7. Subjects with comorbid asthma or (COPD) must be stable with no exacerbations (e.g., no emergency room visits, hospitalization, or oral or parenteral steroid use) within the 3 months before the screening visit. Inhaled corticosteroid use must be limited to stable doses of no more than 1,000 μg/day of beclomethasone (or equivalent) for at least 3 months before screening with plans to continue use throughout the study
  8. Must be able to cease treatment with oral steroids, intranasal steroids, inhaled corticosteroids (except permitted doses listed above for asthma and COPD) at Visit 1 (Day 1/Baseline)
  9. Must demonstrate correct use of the demo EDS
  10. Ability to read and speak English
  11. Must be capable, in the opinion of the investigator, of providing to participate in the study. Subjects must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or lactating
  2. Inability to have each nasal cavity examined for any reason, including nasal septum deviation
  3. Have used XHANCE™ (fluticasone propionate) nasal spray within the past 2 months
  4. Nasal septum perforation
  5. Has had more than 1 episode of epistaxis with frank bleeding in the month before Visit 1 (Day 1/Baseline)
  6. Have evidence of significant mucosal injury or ulceration (e.g. exposed cartilage) on Visit 1 (Day 1/Baseline) nasal examination/nasoendoscopy
  7. History of sinus or nasal surgery within 3 months before Visit 1 (Day 1/Baseline). If >3 months subject should be fully recovered from surgery
  8. Current, ongoing rhinitis medicamentosa (rebound rhinitis)
  9. Have significant oral structural abnormalities, e.g., a cleft palate
  10. Diagnosis of cystic fibrosis
  11. History of Churg-Strauss syndrome or dyskinetic ciliary syndromes
  12. Purulent nasal infection, acute sinusitis, or upper respiratory tract infection within 2 weeks before Visit 1 (Day 1/Baseline). Potential subjects presenting with any of these infections may be rescreened 4 weeks after symptom resolution
  13. Planned sinonasal surgery during the period of the study
  14. Allergy, , or to , steroids, or to any in OPN-375
  15. Exposure to any glucocorticoid treatment with potential for systemic effects (e.g., oral, parenteral, intra-articular, or epidural steroids, high dose topical steroids) within 1 month before Visit 1 (Day 1/Baseline); except as noted in inclusion criteria for subjects with comorbid asthma or
  16. Have nasal candidiasis at Visit 1 (Day 1/Baseline)
  17. History or current diagnosis of any form of glaucoma, ocular hypertension, or intraocular pressure elevation on any form of steroid therapy
  18. History or current diagnosis of the presence (in either eye) of a sub-capsular cataract
  19. Any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study
  20. Recent (within 1 year of Visit 1 (Day 1/Baseline)) history of drug or alcohol abuse, or dependence that, in the opinion of the investigator could interfere with the subject's participation or compliance in the study
  21. Have participated in an drug clinical trial within 30 days of Visit 1 (Day 1/Baseline)
  22. Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    OPN-375 186 mcg BID

    Drug: Fluticasone Propionate

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video

    : Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate

    Time frame: Week 24

Secondary outcomes

  1. Assessment for Safety by Recording Adverse Events and Adverse Events of Special Interests

    Time frame: 24 Weeks, up to 30 days after last dose

  2. Assessment for Safety Through Nasal Examination

    Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma

    Time frame: 24 Weeks, up to 30 days after last dose

  3. Assessment for Safety From Recording Vital Sign - Blood Pressure

    Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)

    Time frame: Baseline, Week 12, Week 24

  4. Assessment for Safety From Recording Vital Sign - Pulse

    measure pulse in beats per minute (bpm)

    Time frame: Baseline, Week 12, Week 24

  5. Assessment for Safety From the Collection of Information for Concomitant Medications Usage

    Time frame: 24 Weeks, up to 30 days after last dose

  6. Total Polyp Grading Score (Sum of Scores From Both Nasal Cavities)

    Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate

    Time frame: Week 24

  7. Number of Subjects With a Change of Greater Than or Equal to 1 Point in Bilateral Polyp Grade

    Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate

    Time frame: Week 24

  8. Number of Subjects With a Polyp Grade of 0 on at Least One Side of the Nose at Each Visit

    Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate

    Time frame: Week 24

  9. Sinonasal Outcome Test 22 (SNOT-22) Total Score

    SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem 1. Very mild problem 2. Mild or slight problem 3. Moderate problem 4. Severe problem 5. Problem as bad as can be

    Time frame: Week 24

  10. Sniffin' Sticks N-butanol Test

    The Sniffin' Sticks n-butanol (Extended test) are used to investigate human olfactory performance by use of odor pens. the Extended Test consists of 3 different subtests: Threshold, Discrimination and Identification. the Threshold test is used to ascertain the patient's olfactory threshold. the Discrimination test requires the patient to differentiate smells. The Identification test requires the patient to identify everyday smells by means of a card with different choices. The result of this test is expressed as the sum of the results of the 3 subtests, the so called TDI score (threshold, discrimination, identification). A score of more than 30 rates as normal, a score of 30 or less indicates hyposmia and a score of 15 and below point to functional anosmia in form of complete loss of the sense of smell or an extremely weakened smell ability.

    Time frame: Week 24

  11. Number of Participants With a PGIC Score of Minimally/Much/Very Much Improved

    The Patient Global Impression of Change (PGIC), is a questionnaire where the patient rates the change in their symptoms. Score range is from 1 (very much improved) to 7 (very much worse)

    Time frame: Week 24

07

Results

Posted Aug 3, 2020

Participant flow

Participant flow — Overall Study
MilestoneOPN-375 186 mcg BID
Started11
Completed9
Not completed2

Outcome measures

PrimaryChange From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video

: Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate

Time frame:
Week 24
Reported as:
Mean · units on a scale
Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video
units on a scaleOPN-375 186 mcg BID
Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video-0.7 ± 0.9
SecondaryAssessment for Safety by Recording Adverse Events and Adverse Events of Special Interests
Time frame:
24 Weeks, up to 30 days after last dose
Reported as:
Count of participants · Participants
Assessment for Safety by Recording Adverse Events and Adverse Events of Special Interests
ParticipantsOPN-375 186 mcg BID
Asthma1
Back pain1
Dizziness1
Dyspnoea1
Fungal skin infection1
Hypotension1
Influenza1
Lacrimation increased1
Nasal discharge discolouration1
Sinusitis1
Tension headache1
Upper respiratory tract infection1
Vasomotor rhinitis1
SecondaryAssessment for Safety Through Nasal Examination

Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma

Time frame:
24 Weeks, up to 30 days after last dose
Reported as:
Count of participants · Participants
Assessment for Safety Through Nasal Examination
ParticipantsOPN-375 186 mcg BID
Epistaxis1
Septal erosion/perforation0
Ulceration/erosion0
SecondaryAssessment for Safety From Recording Vital Sign - Blood Pressure

Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · mmHg
Assessment for Safety From Recording Vital Sign - Blood Pressure
mmHgOPN-375 186 mcg BID - Systolic BPOPN-375 186 mcg BID - Diastolic BP
Baseline130.1 ± 14.383.3 ± 9.3
Week 12127.4 ± 19.682.0 ± 12.9
Week 24131.9 ± 18.881.4 ± 8.7
SecondaryAssessment for Safety From Recording Vital Sign - Pulse

measure pulse in beats per minute (bpm)

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · bpm
Assessment for Safety From Recording Vital Sign - Pulse
bpmOPN-375 186 mcg BID
Baseline71.5 ± 7.1
Week 1273.5 ± 9.1
Week 2476.4 ± 7.4
SecondaryAssessment for Safety From the Collection of Information for Concomitant Medications Usage
Time frame:
24 Weeks, up to 30 days after last dose
Reported as:
Count of participants · Participants
Assessment for Safety From the Collection of Information for Concomitant Medications Usage
ParticipantsOPN-375 186 mcg BID
ACE Inhibitor1
Angiotensin II Receptor Antagonist1
Antianginal1
Anticoagulant1
Antihistamine4
Antifungal Cream1
Ascorbic Acid1
Beta Blocking Agent, selective2
Beta2 Adrenergic Agonist6
Biguanide1
Calcium Channel Blocker1
CNS Muscle Relaxant1
Diuretic2
Electolytes1
HMG CoA Reductase Inhibitors1
Inhaled Corticosteroid2
Inhaled Corticosteroid/Long-acting beta-agonist6
Leukotriene Receptor Antagonists3
Multivitamin2
Nitrate1
Non-steroidal anti-inflammatory drug3
Nuclear factor erythroid-2-related factor1
Selective serotonin reuptake inhibitor1
Synthetic nucleoside analogue1
Other analgesics1
Other antiinflammatorys1
Topical antibiotics2
Proton pump inhibitors1
Testosterone1
Thyroid Hormone2
SecondaryTotal Polyp Grading Score (Sum of Scores From Both Nasal Cavities)

Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate

Time frame:
Week 24
Reported as:
Mean · units on a scale
Total Polyp Grading Score (Sum of Scores From Both Nasal Cavities)
units on a scaleOPN-375 186 mcg BID
Total Polyp Grading Score (Sum of Scores From Both Nasal Cavities)2.4 (2 to 4)
SecondaryNumber of Subjects With a Change of Greater Than or Equal to 1 Point in Bilateral Polyp Grade

Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Subjects With a Change of Greater Than or Equal to 1 Point in Bilateral Polyp Grade
ParticipantsOPN-375 186 mcg BID
Number of Subjects With a Change of Greater Than or Equal to 1 Point in Bilateral Polyp Grade5
SecondaryNumber of Subjects With a Polyp Grade of 0 on at Least One Side of the Nose at Each Visit

Polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior border of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis large polyps reaching below the lower inferior border of the inferior turbinate

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Subjects With a Polyp Grade of 0 on at Least One Side of the Nose at Each Visit
ParticipantsOPN-375 186 mcg BID
Number of Subjects With a Polyp Grade of 0 on at Least One Side of the Nose at Each Visit1
SecondarySinonasal Outcome Test 22 (SNOT-22) Total Score

SNOT-22 is a subject-completed questionnaire that consists of 22 questions. The questions on the SNOT-22 efficacy evaluation were used to calculate a total score. 22 questions are divided among 4 subscales: Rhinologic (7 questions), Ear/Facial Symptoms (4 questions), Sleep Function (3 questions), and Psychological Issues (6 questions). Each item was rated on the 5-point scale. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem 1. Very mild problem 2. Mild or slight problem 3. Moderate problem 4. Severe problem 5. Problem as bad as can be

Time frame:
Week 24
Reported as:
Mean · units on a scale
Sinonasal Outcome Test 22 (SNOT-22) Total Score
units on a scaleOPN-375 186 mcg BID
Sinonasal Outcome Test 22 (SNOT-22) Total Score27.8 ± 16.1
SecondarySniffin' Sticks N-butanol Test

The Sniffin' Sticks n-butanol (Extended test) are used to investigate human olfactory performance by use of odor pens. the Extended Test consists of 3 different subtests: Threshold, Discrimination and Identification. the Threshold test is used to ascertain the patient's olfactory threshold. the Discrimination test requires the patient to differentiate smells. The Identification test requires the patient to identify everyday smells by means of a card with different choices. The result of this test is expressed as the sum of the results of the 3 subtests, the so called TDI score (threshold, discrimination, identification). A score of more than 30 rates as normal, a score of 30 or less indicates hyposmia and a score of 15 and below point to functional anosmia in form of complete loss of the sense of smell or an extremely weakened smell ability.

Time frame:
Week 24
Reported as:
Mean · units on a scale
Sniffin' Sticks N-butanol Test
units on a scaleOPN-375 186 mcg BID
Sniffin' Sticks N-butanol Test16.5 ± 6.9
SecondaryNumber of Participants With a PGIC Score of Minimally/Much/Very Much Improved

The Patient Global Impression of Change (PGIC), is a questionnaire where the patient rates the change in their symptoms. Score range is from 1 (very much improved) to 7 (very much worse)

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants With a PGIC Score of Minimally/Much/Very Much Improved
ParticipantsOPN-375 186 mcg BID
Number of Participants With a PGIC Score of Minimally/Much/Very Much Improved9

Adverse events

Collected over 24 weeks, and up to 30 days after the last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPN-375 186 mcg BID0/11 (0%)0/11 (0%)1/11 (9.1%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventOPN-375 186 mcg BID
DyspneaCardiac disorders1/11
AsthmaRespiratory, thoracic and mediastinal disorders1/11
Back PainMusculoskeletal and connective tissue disorders1/11
DizzinessNervous system disorders1/11
Fungal Skin InfectionInfections and infestations1/11
HypotensionCardiac disorders1/11
InfluenzaInfections and infestations1/11
Lacrimation IncreasedEye disorders1/11
Nasal Discharge DiscolourationRespiratory, thoracic and mediastinal disorders1/11
SinusitisInfections and infestations1/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)OPN-375 186 mcg BID
Mean54.6 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)OPN-375 186 mcg BID
Female3
Male8
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OPN-375 186 mcg BID
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White10
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)OPN-375 186 mcg BID
United States11
Total Polyp Grading Score (sum of scores from both nasal cavities)
Total Polyp Grading Score (sum of scores from both nasal cavities)(units on a scale)OPN-375 186 mcg BID
Mean3.1 (2 to 6)
Sinonasal Outcome Test 22 (SNOT-22) Total Score
Sinonasal Outcome Test 22 (SNOT-22) Total Score(units on a scale)OPN-375 186 mcg BID
Mean48.8 (26 to 74)
Sniffin' Sticks n-butanol tests
Sniffin' Sticks n-butanol tests(units on a scale)OPN-375 186 mcg BID
Mean11.8 ± 6.5
08

Study locations

2 sites
  • University of Colorado SOM, Department of Otolaryngology
    Aurora, Colorado 80045, United States
  • University of Texas Health Science Center at Houston, McGovern Medical School, Dept. of Otolaryngology, Head and Neck Surgery
    Houston, Texas 77030, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Feb 2019, 8 months.

Results were first posted in Aug 2020, 1 year 5 months after primary completion.

Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 8 months is below that.

Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2018
First posted
Jul 18, 2018
StartActual
Jun 7, 2018
Primary completionActual
Feb 22, 2019
CompletionActual
Feb 22, 2019
Results first posted
Aug 3, 2020
Last update
Aug 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03591068
Lead sponsor
Optinose US Inc.
Responsible party
Sponsor
First posted
Jul 18, 2018
Start date
Jun 7, 2018
Primary completion
Feb 22, 2019
Completion
Feb 22, 2019
Results posted
Aug 3, 2020
Last update
Aug 3, 2020

Study contacts

Jennifer Carothers
study director · Optinose US Inc.
John Messina
study chair · Optinose US Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion